Our commitment to accessibility is underscored by the affordability of our product. The HemaClinix device is notably more cost-effective to produce compared to similar devices in the market. This efficiency allows us to offer the device to end-users at a fraction of the cost, making regular coagulation system assessments more financially accessible to a broader population.
The user-friendly nature of our device is a key feature. Requiring no calibration, it is designed for ease of use in diverse settings. Moreover, our production capabilities enable us to meet high demand by producing the device in large quantities, ensuring widespread availability.
In terms of market penetration, our target audience encompasses the extensive population of patients on anticoagulant therapy, with a staggering 800 million PT/INR assays performed annually worldwide. We aim to address this demand by providing a simpler, more cost-effective solution for PT/INR testing, thereby creating a positive impact on healthcare accessibility.
To uphold the highest standards of quality and reliability, we are diligently pursuing research and development initiatives. This includes planned clinical trials to validate the accuracy of our device and secure necessary regulatory approvals. As part of our strategic growth, we are actively exploring potential locations for our operations, with Fredericton emerging as a strong contender due to its strategic geographical location and business-friendly environment. HemaClinix is poised to make a lasting contribution to healthcare accessibility in Canada and globally, ushering in a new era of point-of-care testing solutions.
